News

March 18, 2019

Some PC Patients Can Safely Receive Short but Intense Course of Radiation

News

Stereotactic body radiotherapy (SBRT), which delivers higher doses of radiation over a significantly shorter period of time, can be safely given to men with low- or intermediate-risk prostate cancer with ... Read more

March 14, 2019

Provenge Better for African-Americans Than Men of Other Ethnicities, Analysis Shows

News

Provenge (sipuleucel-T), a treatment approved in the U.S. for metastatic castration-resistant prostate cancer, significantly increased the number of patients alive at three years, compared to a placebo, a retrospective ... Read more

March 13, 2019March 13, 2019

Trial To Test Lynparza-Zytiga Combo Recruiting Men with Metastatic Castration-resistant Prostate Cancer

News

A Phase 3 trial is recruiting men to test a combination of Lynparza (olaparib) and Zytiga (abiraterone acetate) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Named PROpel ... Read more

March 11, 2019

Zejula Cuts Tumor Burden in Significant Proportion of Advanced PC Patients

News

Four in 10 adults with metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations respond to treatment with Zejula (niraparib), according to early results of an ongoing Phase 2 trial. The GALAHAD study ... Read more

March 7, 2019

Darolutamide Delays Metastasis in High-risk CRPC Patients, Phase 3 Trial Shows

News

Adding the androgen receptor inhibitor darolutamide to androgen deprivation therapy (ADT) extends by 22 months the time men with castration-resistant prostate cancer live without metastasis, without increasing the incidence of adverse events, results ... Read more

March 6, 2019

Opdivo-Yervoy Combo Shows Signs of Activity in CRPC Patients with Metastases

News

A combination of Bristol-Myers Squibb’s immune checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) reduces tumor burden in castration-resistant prostate cancer patients whose tumors have spread, interim Phase 2 results show. Findings from the CheckMate ... Read more

March 4, 2019March 4, 2019

Xtandi, Zytiga Better for African-Americans Than Whites With Advanced Prostate Cancer, Research Finds

News

African-Americans with metastatic castration-resistant prostate cancer live longer after treatment with the androgen inhibitors Zytiga (abiraterone acetate) or Xtandi (enzalutamide) than white men, a new study reports. Historically, African-Americans ... Read more

February 28, 2019

Leap’s DKN-01 Enters Testing in Metastatic Castration-resistant Prostate Cancers

News

Leap Therapeutics is launching a Phase 1/2 trial to study its lead candidate DKN-01, alone or in combination with chemotherapy, for the treatment of metastatic castration-resistant prostate cancer (CRPC) patients ... Read more

February 27, 2019

Physicians’ Education Resource to Host 12th Annual Prostate Cancer Congress

News

The 12th annual New York GU: Annual Interdisciplinary Prostate Cancer Congress and Other Genitourinary Malignancies will focus on essential clinical topics in disease management. The meeting, hosted by Physicians’ Education ... Read more

February 21, 2019

PSA Testing Cuts Deaths, Shows Value of Long-Term Screening

News

A blood test measuring the levels of PSA — a well-known marker of prostate cancer — cuts deaths from the disease by nearly 30%, the longest screening study on ... Read more

Pin It on Pinterest